Answers are grounded in this paper and cite their sources.
INTRODUCTION It is now established that cancer disproportionately impacts racial/ethnic minority groups, as reflected in a higher risk for cancer development, a more advanced stage at presentation, and worse prognosis in affected patients. This is consistently observed, across the most common types of cancer in men and women including breast, lung, prostate, and colorectal cancers, and extends to several hematologic malignancies such as multiple myeloma. It is believed that multiple factors interact to contribute to these racial/ethnic disparities in cancer incidence, burden, and mortality including differences in diet, environmental exposures, socioeconomic status, biologic and genetic determinants, clinical comorbidities, treatment compliance, and access to optimal health care and treatment. Even among cancer survivors, healthrelated quality of life remains poor and associated with social needs. Despite available evidence, we remain far from a full understanding of the independent and combinatorial effects of the various contributors to racial/ethnic disparities in cancer outcomes. Addressing such a gap in knowledge remains essential to direct change and inform policies and standards for cancer care that can achieve health equity. However, we cannot address this gap in the blind, and that is where the role of cancer research remains of utmost importance. Cancer research directed to understanding variations in cancer outcomes across racial/ethnic groups can shed more light on specific and modifiable risk factors. More importantly, ensuring diversity in therapeutic clinical trials that reflects known incidence and burden of cancer in various racial/ethnic groups will allow appropriate interpretation of risk/benefit and tailored management with emerging therapies. Here, we revisit the status quo of racial/ethnic disparities in cancer clinical trial participation and discuss potential solutions to tackle them, especially from the viewpoint of a drug developer. It is no secret that the pharmaceutical industry remains a key player and driver of cancer research and novel drug development. Our intention is to call for action from our colleagues in the industry, while equally highlighting the role of collaboration with other partners from the research community in ensuring modern clinical trials reach all patients representative of the cancer type the trial is evaluating when it comes to ethnicity or race.
No takes yet. Share an insight, caveat, or question.
Habr et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: